{"id":39185,"date":"2023-09-11T04:20:04","date_gmt":"2023-09-11T02:20:04","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=39185"},"modified":"2023-10-02T04:21:40","modified_gmt":"2023-10-02T02:21:40","slug":"ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/","title":{"rendered":"Ascendis Pharma enters into 150 MUSD royalty agreement: Danish Biotech Weekly (37)"},"content":{"rendered":"\n

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. <\/em><\/p>\n\n\n\n

In the past week, Genmab reported a positive phase 3 study with overall improved survival, Ascendis Pharma entered into an agreement worth 150 MUSD upfront, and SynAct Pharma got chrushed after a failed phase 2 study with their lead-candidate.<\/strong><\/p>\n\n\n\n

The past week was full of exciting news with 8 of the 20 listed Danish biotech companies publishing news. 10 of the 20 companies had a positive share price development the past week and 8 companies have a positive share price performance year to date. Fluoguide is back as the best performing stock year-to-date, while the SynAct Pharma stock price crashed.<\/strong><\/p>\n\n\n\n

\n
Register for the Danish Biotech Weekly newsletter<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Company news the past week<\/strong><\/p>\n\n\n\n

Ascendis Pharma<\/strong><\/p>\n\n\n\n

Ascendis Pharma Reports Second Quarter 2023 Financial Results (Link<\/a>)<\/p>\n\n\n\n

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement (Link<\/a>)<\/p>\n\n\n\n

New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism (Link<\/a>)<\/p>\n\n\n\n

Biosergen<\/strong><\/a><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Cessatech<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

CS Medica<\/strong><\/a><\/p>\n\n\n\n

 CS MEDICA’s Joint Venture with RongShi Successfully Represented at CPHI & PMEC China 2023 (Link<\/a>)<\/p>\n\n\n\n

Curasight<\/strong><\/a><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Evaxion Biotech<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Expres2ion<\/strong><\/p>\n\n\n\n

ExpreS2ion announces TO 8 warrant exercise price and start of exercise period (Link<\/a>)<\/p>\n\n\n\n

Fluoguide<\/strong><\/p>\n\n\n\n

FluoGuide receives Danish award for the best share price performance since IPO (Link<\/a>)<\/p>\n\n\n\n

Genmab<\/strong><\/p>\n\n\n\n

Genmab and Seagen Announce That TIVDAK\u00ae (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy (Link<\/a>)<\/p>\n\n\n\n

Gubra<\/strong><\/p>\n\n\n\n

Gubra submits clinical trial application (CTA) for first-in-human amylin trial (Link<\/a>)<\/p>\n\n\n\n

Initiator Pharma<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

IO Biotech<\/strong><\/p>\n\n\n\n

IO Biotech Announces Participation in Upcoming Investor Conferences<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Pila Pharma<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Saniona<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Scandion Oncology<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

SynAct Pharma<\/strong><\/p>\n\n\n\n

Synact Pharma announces top line data from the 12-week EXPAND P2b clinical trial in severely active newly diagnosed rheumatoid arthritis patients (Link<\/a>)<\/p>\n\n\n\n

ViroGates<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Zealand Pharma<\/strong><\/p>\n\n\n\n

Zealand Pharma to participate in upcoming healthcare conferences in September 2023<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Y-mAbs Therapeutics<\/strong><\/p>\n\n\n\n

Y-mAbs to Participate at Upcoming Investor Conferences in September<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

2cureX<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

SELECTED CASES<\/strong><\/p>\n\n\n\n

\n
\n

Biosergen<\/a><\/strong><\/h2>\n\n\n\n
\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\n
Investment case<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

Curasight<\/a><\/strong><\/h2>\n\n\n\n
\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\n
Investment Case<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

CS Medica<\/a><\/strong><\/h2>\n\n\n\n
\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\n
Investment case<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

\n
Interested in Nordic healthcare stocks? View our weekly Nordic newsletter here (in Danish)<\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

SHARE PRICE DEVELOPMENTS<\/strong><\/p>\n\n\n\n

On average, the Danish biotech stocks delivered a negative share price performance last week of -3.7%. Cessatech A\/S rose more 60% without publishing any news. Ascendis Pharma ended up falling 1% after a deal with Royalty Pharma regarding SKYTROFA. Ascendis Pharma recieves $150 million in exchange for a 9.15% royalty on U.S. net SKYTROFA revenue. Furthermore, SynAct Pharma got chrushed with a 85% fall after their failed study, where Resomelagon did not meet the primary endpoint. The company still have preclinical studies with other compounds as well as Resomelagon in other indications but the failed study will have a significant impact on the company going forward. The best stocks year-to-date include Curasight, Cessatech Fluoguide, <\/strong>and Saniona<\/strong> after soaring 98-145%. Overall, the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 0.3%<\/strong>. However, it is driven by the few companies delivering very positive returns.<\/p>\n\n\n\n

Read more about Curasight (in Danish):<\/strong><\/mark> Et succesfuldt kvartal for Curasight med mere i vente<\/a><\/p>\n\n\n\n

Overview of share price developments the past week, year-to-date and last twelve months<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. In the past week, Genmab reported a positive phase 3 study with overall improved survival, Ascendis Pharma entered into an agreement worth 150 MUSD […]<\/p>\n","protected":false},"author":11,"featured_media":37397,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[9],"tags":[],"class_list":["post-39185","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-en-investeringscases"],"acf":[],"yoast_head":"\nAscendis Pharma enters into 150 MUSD royalty agreement: Danish Biotech Weekly (37) | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascendis Pharma enters into 150 MUSD royalty agreement: Danish Biotech Weekly (37) | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. In the past week, Genmab reported a positive phase 3 study with overall improved survival, Ascendis Pharma entered into an agreement worth 150 MUSD […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-11T02:20:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-02T02:21:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1015\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"Ascendis Pharma enters into 150 MUSD royalty agreement: Danish Biotech Weekly (37)\",\"datePublished\":\"2023-09-11T02:20:04+00:00\",\"dateModified\":\"2023-10-02T02:21:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/\"},\"wordCount\":604,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"articleSection\":[\"All investment Cases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/\",\"name\":\"Ascendis Pharma enters into 150 MUSD royalty agreement: Danish Biotech Weekly (37) | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"datePublished\":\"2023-09-11T02:20:04+00:00\",\"dateModified\":\"2023-10-02T02:21:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"width\":1015,\"height\":533},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"All investment Cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/en-investeringscases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Ascendis Pharma enters into 150 MUSD royalty agreement: Danish Biotech Weekly (37)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ascendis Pharma enters into 150 MUSD royalty agreement: Danish Biotech Weekly (37) | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/","og_locale":"en_US","og_type":"article","og_title":"Ascendis Pharma enters into 150 MUSD royalty agreement: Danish Biotech Weekly (37) | Kapital Partner A\/S","og_description":"Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. In the past week, Genmab reported a positive phase 3 study with overall improved survival, Ascendis Pharma entered into an agreement worth 150 MUSD […]","og_url":"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2023-09-11T02:20:04+00:00","article_modified_time":"2023-10-02T02:21:40+00:00","og_image":[{"width":1015,"height":533,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","type":"image\/png"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"Ascendis Pharma enters into 150 MUSD royalty agreement: Danish Biotech Weekly (37)","datePublished":"2023-09-11T02:20:04+00:00","dateModified":"2023-10-02T02:21:40+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/"},"wordCount":604,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","articleSection":["All investment Cases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/","url":"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/","name":"Ascendis Pharma enters into 150 MUSD royalty agreement: Danish Biotech Weekly (37) | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","datePublished":"2023-09-11T02:20:04+00:00","dateModified":"2023-10-02T02:21:40+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","width":1015,"height":533},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/ascendis-pharma-enters-into-150-musd-royalty-agreement-danish-biotech-weekly-37\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"All investment Cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/en-investeringscases\/"},{"@type":"ListItem","position":3,"name":"Ascendis Pharma enters into 150 MUSD royalty agreement: Danish Biotech Weekly (37)"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/39185"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=39185"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/39185\/revisions"}],"predecessor-version":[{"id":39188,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/39185\/revisions\/39188"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/37397"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=39185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=39185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=39185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}